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1. Introduction 
1.1. Oral Squamous Cell Carcinoma 
1.1.1. Epidemiology 
Squamous cell carcinoma of the head and neck (SCCHN) is a cancer of the 
upper aerodigestive tract (including the nasal cavity, oral cavity, pharynx and 
larynx), the salivary glands and the paranasal sinuses (H. Mehanna, Paleri, 
West, & Nutting, 2010). 
One of the most frequent types of head and neck cancers is oral squamous cell 
carcinoma (OSCC). It takes the sixth place among the most common cancers 
worldwide, and leads mostly to death (Jemal et al., 2008). It covers 90% of all 
neoplastic epithelial neoplasms of the oral cavity and considered accordingly as 
the most common malignancy in it (Silverman, 1998) and represents 3% of total 
cancers in the world (Scully & Felix, 2006). It is noticable that the incidence of 
oral cancer is frequently between the age of 40 and 60 years; men are affected 
twice more often than women (Messadi, 2013). 
Anually 10,000 new cases of oral and pharyngeal cancer are diagnosed in 
Germany; 4,000 of these lead to death every year (Hertrampf, Wiltfang, 
Katalinic, Timm, & Wenz, 2012). The global incidence of cancer of the lip and 
oral cavity is estimated to be 263,900 new cases and 128,000 deaths caused 
from oral cavity cancer in 2008 (Jemal et al., 2011). The highest incidence rates 
for oral cancer are characterized in the regions of South and Southeast Asia 
(e.g. Bangladesh, India, Pakistan, and Sri Lanka), Australia, central and Eastern 
Europe, Northern America, as well as parts of Southern Africa. 
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1.1.2. Malignant transformation of oral mucosa 
When the squamous epithelium is affected by several genetic alterations, this 
will lead to a highly complex multi-step process known as oral carcinogenesis. 
Figure 1 shows the different stages of oral carcinogenesis.  
Figure 1: The different stages of oral carcinogenesis 
(A) non-malignant tissue, (B) mild dysplasia; slightly atypical cells in the basal layer of 
epithelium, (C) moderate dysplasia; the atypical cells proliferate into the middle third of the 
epithelium, (D) severe dysplasia; the atypia arrives at the upper third of the epithelium                                                                  
Abbreviations: N.T. = non-malignant tissue; SIN = squamous intraepithelial neoplasia 
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The clinical observation of oral precancerous lesions is significant, because 
these lesions could transform into OSCC (Guillaud, Zhang, Poh, Rosin, & 
MacAulay, 2008; Ho et al., 2009). Many studies have indicated a rate between 
6.6% and 36.4% for the risk of malignant transformation, although a recent 
study has limited it to 12.1% (Arduino et al., 2009; H. M. Mehanna, Rattay, 
Smith, & McConkey, 2009). Therefore, an early diagnosis for the precancerous 
lesions in the oral cavity is recommended using the molecular biology 
techniques, by which the detection of alterations can be earlier and the 
identification of high-risk oral cancer patients can be faster (Joseph, 2002; 
Tanaka, Tanaka, & Tanaka, 2011). The most common precancerous lesions 
that may develop into OSCC are leukoplakia, erythroplakia, oral submucous 
fibrosis, palatal lesion of reverse cigar smoking, discoid lupus erythematosus, 
dyskeratosis congenita and epidermolysis bullosa (Warnakulasuriya, Johnson, 
& van der Waal, 2007). Leukoplakia and erythroplakia are the most two lesions 
among the pre-mentioned ones that tend more to malignancy in the oral cavity 
(Liu et al., 2010; van der Waal, 2009). In addition, oral lichen planus and oral 
submucous fibrosis are also considered as precancerous with a lower malignant 
transformation into OSCC as in leukoplakia (van der Waal, 2009). The potential 
mechanism of oral carcinogenesis is explained by the field cancerization 
concept, which hypothesizes that the exposure to carcinogenic factors can 
stimulate genetic defects in the epithelium of the upper aerodigestive tract, 
leading to development of multiple lesions in this epithelium (Sreedhar, 
Narayanappa Sumalatha, & Shukla, 2014). The theory of  field cancerization 
proposes that sometimes mutations can be developed in the exons of tumor 
suppressor genes (Tanaka et al., 2011). An important tumor suppressor is 
the p53 tumor-suppressor gene. P53 is a well-known gene and is observed in 
several areas of premalignant leukoplakia and carcinoma in one oral cavity 
(Boyle et al., 1993). 
One of the most important signs of predicting the malignant transformation is 
the presence of epithelial dysplasia, which can be only histologically diagnosed 
(Hanken et al., 2013). Nevertheless, epithelial dysplasia can only predict that 
there is a risk of malignant transformation (Messadi, 2013). 
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2. The Hallmarks of Cancer 
In January 2000, Hanahan and Weinberg published an important paper, in 
which a list of 6 characteristics for the transformation of normal cells into 
cancerous had been proposed. (1) Self-sufficiency in growth signals, (2) 
insensitivity to antigrowth signals, (3) ability to evade programmed cell death 
(apoptosis), (4) limitless replicative potential, (5) sustained angiogenesis, (6) 
and tissue invasion and metastasis represent the hallmarks of cancer, which 
are shared among most if not all cancer cells (Hanahan & Weinberg, 2000). 
Hanahan and Weinberg have suggested that each of these capabilities must be 
acquired in the normal human cell in order to enable the malignant 
transformation. Otherwise, the multiple body anti-cancer mechanisms will inhibit 
that. Therefore, the risk of developing cancer during the human lifetime is 
relatively low (Hanahan & Weinberg, 2000). In 2011, Hanahan and Weinberg 
proposed 4 new hallmarks and they were the ability to evade the immune 
system, the presence of inflammation, the tendency towards genomic instability, 
and dysregulated metabolism (Hanahan & Weinberg, 2011). Epidermal growth 
factor receptor (EGFR) is well-known to be associated with head and neck 
cancers and anti-EGFR agents are being investigated as a potential adjuvant 
therapy for oral cancer (Simabuco et al., 2014). An abnormal activation of 
EGFR gene is associated with self-sufficiency in growth signals, evading 
apoptosis and other hallmarks of cancer (Tseng & He, 2013). 
2.1. Self-sufficiency in growth signals  
Normal human cells depend for their division on external growth signals, which 
are transmitted through the receptors on the cell membrane. The division of 
normal cells is not possible in the absence of these signals. On the contrary, 
cancer cells not only show a very low dependence on external growth signals, 
but also can even produce their signals (Hanahan & Weinberg, 2000). 
Furthermore, it has become apparent that tumors tend to have cell surface 
receptors overexpression, in which any binding between the receptor and its 
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ligand may direct a cell growth (Fedi, 1997). In OSCC, high levels of mRNA for 
EGFR have been identified. (Grandis & Tweardy, 1993). 
2.1.1. Epidermal growth factor receptor (EGFR) 
The EGFR family has been reported to be involved in the development of many 
cancers as well as to be contributed to most hallmarks of cancer (Holbro, 
Civenni, & Hynes, 2003). Over the past decades, it has been shown that EGFR 
represents a promising target for cancer therapy medications in advanced head 
and neck cancers (Aquino et al., 2012). Therefore, a good understanding of this 
receptor should be obtained to know its precise etiology. 
EGFR belongs to a family of tyrosine kinase receptors (RTKs), which includes 
four members: EGFR (also known as ErbB1 or HER1), ErbB2 (HER2), ErbB3 
(HER3) and ErbB4 (HER4) (Hynes & Lane, 2005). Each of the ErbB receptors 
is a 170 kDa glycoprotein and has a structure consisting of an extracellular 
region including a ligand-binding domain, a transmembrane region that attaches 
the receptor to the cytoplasmic membrane and a cytoplasmic protein tyrosine 
kinase domain (Reuter, Morgan, & Eckardt, 2007; Tzahar et al., 1996). 
When a ligand binds to its corresponding receptor of the ErbB family, a 
formation of either homodimers (between two identical receptors e.g. 
EGFR/EGFR) or heterodimers (between two different receptors e.g. 
ErbB2/ErbB4) is induced. This leads to activation of the intracellular kinase 
domain through autophosphorylation, followed by initiating lots of intracellular 
signaling events, such as mitogen-activated protein kinase (MAPK), 
phosphatidylinositol-3-kinase (PI3K), AKT, Janus kinase (Jak), mammalian 
target of rapamycin (mTOR), signal transducer and activator of transcription 
(STAT) and protein kinase C (PKC) pathways (Kalyankrishna & Grandis, 2006; 
Rogers, Harrington, Rhys-Evans, P, & Eccles, 2005; Yarden & Sliwkowski, 
2001). Afterwards, the downstream signaling regulates many cell functions, 
such as cell proliferation, survival, metastasis, and angiogenesis (Reuter et al., 
2007). 
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Activation of EGFR (Figure 2) depends on the bind to specific ligands. 
Currently, the eight known ligands that bind to EGFR are epidermal growth 
factor (EGF), transforming growth factor α (TGF-α), heparin-binding EGF (HB-
EGF), amphiregulin (AREG), epiregulin (EPR), betacellulin, epigen and crypto 
(Fischer, Hart, Gschwind, & Ullrich, 2003). It seems that ErbB2 does not bind to 
any ligands, while ErbB3 has no tyrosine kinase activity. Therefore, both of 
them act as heterodimers with the others of the ErbB family, and can be hereby 
activated (Citri, Skaria, & Yarden, 2003). 
EGFR can also be activated indirectly through cellular stresses, Ultraviolet light 
and γ-irradiation, which lead to phosphorylation (Fischer et al., 2003) . 
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Figure 2: ErbB/HER signaling and the impact of TKIs on it. 
The ErbB members signal through MAPK, PI3K, Akt and many other intracellular signaling 
events regulate cell proliferation, survival, metastasis, and angiogenesis. EGFR is frequently 
over-expressed, mutated or amplified in many types of cancer, making it an important target for 
therapies with monoclonal antibodies or special TKI’s in those cancers. The mechanism of 
EGFR-TKI’s like gefitinib and erlotinib depends on blocking the tyrosine kinase activity of the 
cancer cell.                                                                                                                 
Abbreviations: βCEL = betacellulin; EGF = epidermal growth factor; EGFR = epidermal growth 
factor receptor; EPG = epigen; HB-EGF = heparin-binding EGF; TGF-α = transforming growth 
factor α 
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2.1.2. Mutant EGFR (E746-A750del) 
Increased activation of EGFR can occur as a result of several mechanisms, 
such as EGFR overexpression due to gene amplification or transcriptional up-
regulation, overproduction of EGFR ligands, and EGFR mutations 
(Kalyankrishna & Grandis, 2006; Rogers et al., 2005). The overexpression of 
EGFR has been observed in 80-100% of SCCHN (Kalyankrishna & Grandis, 
2006; Reuter et al., 2007). To date, targeting EGFR with cetuximab, which is a 
chimeric anti-EGFR monoclonal antibody (mAb), has been most successful in 
gaining favorable clinical outcomes in SCCHN (Cohen, 2013). But 
unfortunately, the presence of EGFR in OSCC has been correlated with poor 
treatment outcomes, which has made it controversial whether EGFR is a 
promising therapeutic target in OSCC (Choi & Myers, 2008; Grobe et al., 2013; 
Monteiro, Diniz-Freitas, Garcia-Caballero, Forteza, & Fraga, 2010; Oliveira & 
Ribeiro-Silva, 2011). A study has demonstrated a strong association between 
EGFR, which has been evaluated by immunohistochemical staining (IHC) with 
advanced lymph node involvement (Grobe et al., 2013). Nevertheless, EGFR 
may affect also the survival rate of patients with OSCC according to Laimer et 
al., since he has considered EGFR overexpression in patients with OSCC and 
oropharynx as an independent prognostic marker leading to reduced survival. 
Consequently, EGFR represents an important target for therapies with 
monoclonal antibodies or special tyrosine-kinase inhibitors (TKI) in these 
patients (Laimer et al., 2007). 
Smoking and alcohol consumption are primary risk factors of OSCC (Wang et 
al., 2012). However, some research has confirmed a correlation between EGFR 
and never-smoking in a subset of patients with non-small-cell lung cancer 
(NSCLC)  
(Marchetti et al., 2005; Shigematsu et al., 2005). It seems that there are other 
genetic factors including DNA mismatch repair, and environmental factors 
including radiation or second-hand smoke involved in EGFR mutations (Riely, 
Politi, Miller, & Pao, 2006). Never-smokers with EGFR mutations have shown a 
positive response to EGFR-TKI’s like gefitinib and erlotinib, which inhibit 
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tyrosine kinase activity by reducing tumor cell proliferation and inducing 
apoptosis (Lynch et al., 2004; Paez et al., 2004; Pao, Miller, Zakowski, et al., 
2004; Riely et al., 2006). EGFR mutations have been reported to occur in exons 
18 to 21, which encode the tyrosine kinase domain. Nearly 90 % of all EGFR 
mutations are deletions of four amino acids (LREA) at positions 747–750 
localized in exon 19, and a point mutation (L858R) arising as a result of 
replacing the amino acid leucine with arginine at position 858 within exon 21. 
These mutations make the activation of EGFR independent of binding with its 
ligands, and in case of ligand stimulation, a prolonged receptor kinase activity 
will be initiated (Amann et al., 2005; Lynch et al., 2004). Most patients with 
these mutations, especially delE746-A750 and the L858R point mutation, have 
shown increased sensitivity to EGFR-TKI's such as gefitinib and erlotinib and 
have survived for a longer time than those patients without EGFR mutations 
(Figure 3) (Kawahara et al., 2010; Mitsudomi et al., 2005; Ono & Kuwano, 2006; 
Takano et al., 2005; Yu et al., 2009). In addition, the combination between 
erlotinib or gefitinib with cytotoxic chemotherapy has improved the overall 
survival among patients, who had a medical history of NSCLC, EGFR mutations 
and never-smoking. (Riely et al., 2006). 
Recently, direct polymerase chain reaction (PCR) based sequencing of EGFR 
tyrosine kinase domains have described EGFR mutations in OSCC (Huang et 
al., 2009; Tushar & Ramanathan, 2013). 
IHC staining (is widely used for the detection of biomarkers in tumor cells, and it 
has a significant role in identification of carcinogenesis and deciding the cancer 
patient treatment (Cummings, Raynaud, Jones, Sugar, & Dive, 2010). A study 
has used IHC for the detection of E746-A750del mutation depending on a 
specific antibody. This method has shown its efficiency in EGFR mutations 
diagnose when used in combination with DNA sequence (Kawahara et al., 
2010). 
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Figure 3: Frequencies of mutations in exons 18-21 in the EGFR gene in the EGFR 
inhibitor-responsive tumors. Reproduced from (Sharma, Bell, Settleman, & Haber, 2007) 
Exons 18–21 in the tyrosine kinase domain of the EGFR gene are enlarged. Approximately 90 
% of those mutations are deletion of the codons 746 - 750 localized in exon 19, and (point 
mutation L858R, substitution Leucin to Arginin in codon 858) localized in exon 21.                                            
Abbreviations: TM = Transmembrane region 
2.1. Evading programmed cell death (Apoptosis) 
When cells become senescent, they will undergo a programmed death 
(Williams, 1991), which is resisted by most if not all cancer types (Hanahan & 
Weinberg, 2000).  The two responsible components for apoptosis are classified 
into: sensors, which decide through normal and abnormal situations between 
survival or death of the cell; and effectors, which lead to apoptosis. Moreover, 
p53 represents an apoptotic factor (Symonds et al., 1994). However, the cancer 
cells have the capacity to overcome apoptosis through mutations in p53 (Harris, 
1996) and other ways (Hanahan & Weinberg, 2000). Several studies have 
demonstrated that p53 is mutated in 25-69% of oral cancers (Choi & Myers, 
2008). Human papillomavirus (HPV) such as HPV16 and HPV18 subtypes 
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cause the degradation of p53 (Nagpal, Patnaik, & Das, 2002). Therefore, 
cancer cells infected with HPV may evade apoptosis. 
2.1.1. Human papillomavirus (HPV) 
HPVs are members of the papillomaviridae family, which consists of small and 
non-enveloped DNA viruses. The genome is composed of three regions: the 
early region, the late region and the non-coding region. The early region covers 
about 50% of the genome and encodes the early regulatory proteins (E1, E2, 
E4, E5, E6 and E7 and also E8 in HPV-31) (McLaughlin-Drubin, Meyers, & 
Munger, 2012; Zheng & Baker, 2006). 
It has become evident that HPV16 is the most common HPV type detected in 
oral cancers, followed by HPV18 (Isayeva, Li, Maswahu, & Brandwein-Gensler, 
2012). HPV16/18 has been reported to be involved in lung carcinogenesis in 
non-smoking patients with NSCLC (Cheng et al., 2001). Another study has also 
reported an association between HPV infection and non-smokers with OSCC 
(Laco et al., 2011). Although HPV has shown an etiological relation to a subset 
of patients with SCCHN, it is still controversial to date, whether HPV infection 
plays a role in the carcinogenesis of OSCC (Isayeva et al., 2012; Rampias, 
Sasaki, Weinberger, & Psyrri, 2009). 60 publications studied between the years 
2000-2011 were reviewed by Isayeva et al. revealed a weighted prevalence of 
20.2% HPV DNA in 4,195 oral cavity cancer patients (range: 0%-94.7%) (Table 
1) (Isayeva et al., 2012). 
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Table 1: HPV DNA detection frequencies in oral cavity carcinomas (Isayeva et al., 2012) 
Author Year Country Method, primers, amplicon detection 
Number 
of HPV 
positive 
cancers 
Total 
cancers 
studied 
HPV 
positive 
cancers 
(%) 
Badaracco 2007 Italy PCR, MY09/MY11, GP5/GP6 8 60 13.3 
Baez 2004 Puerto Rico PCR, HPV16 E6/E7 ORF 13 36 36.1 
Bagan 2007 Spain PCR, MY09/MY11 0 6 0.0 
Balderas-
Laenza 
2007 Mexico PCR, MY09/MY11, GP5/GP6 26 62 41.9 
Barwad 2011 India PCR, MY09/MY11, not nested, agarose gel 16 34 47.1 
Boscolo- 
Rizzo 
2009 Italy PCR, HPV16 specific primers 2 10 20.0 
Bouda 2000 Greece PCR 18 19 94.7 
Boy 2006 South 
Africa 
PCR, HPV16/18 specific primers 7 59 11.9 
Braakhuis 2004 Netherlands PCR, GP5/GP6, typing 6 106 5.7 
Correnti 2004 Venezuela PCR, MYO9/MY11, not nested, agarose gel, 
Digene Sharp Signal Assay typing 
8 16 50.0 
 
Dahlgren 
 
2004 
 
Scandinavia 
 
PCR, GP5/GP6, CPI/CPIIG, agarose gel 
 
2 
 
85 
 
2.4 
Deng 2011 Japan PCR, MYO9/MY11, GP5/GP6, E1 consensus 
primers 
9 25 36.0 
Dong 2003 USA PCR, HPV16/18 specific primers 3 16 18.8 
Elango 2011 India PCR, MY09/MY11, GP5/GP6, HPV16 specific 
primers 
30 60 50.0 
El-Mofty 2003 USA PCR, SPF10, INNO-LiPA line probe 0 15 0.0 
Feher 2009 Hungary PCR, MY09/MY11, GP5/GP6 31 65 47.7 
Fischer 2003 Germany PCR, L1 consensus primers 0 2 0.0 
Fujita 2008 Japan PCR, SPF10, sequencing 11 23 47.8 
Furniss 2007 USA PCR, SPF1A, SPF2B, HPV16 E6 specific primers 38 150 25.3 
Gillison 2000 USA PCR, MY09/MY11, HPV16E7 HPV18E7 Dot blot 10 84 11.9 
Gonzalez 2007 Argentina PCR, MY09/MY11, GP5/GP6, 15 25 60.0 
Gudleviciene 2009 Lithuania PCR, HPV16/18 specific primers, agarose gel 1 13 7.7 
Ha 2002 USA PCR, HPV16 E6/E7 primers, real time quantitative 
PCR 
1 34 2.9 
Halimi 2011 Iran PCR, MY09/MY11 then typed, agarose gel 6 30 20.0 
Hansson 2005 Scandinavia PCR, MY09/MY11, GP5/GP6, agarose gel, 
sequenced 
15 85 17.6 
Harris 2011 USA PCR, MY09/MY11, GP5/GP6, type specific primers 2 25 8.0 
Herrero 2003 Multiple 
countries 
PCR, GP5/GP6, enzyme immune assay typing 30    766 3.9 
 Ibieta   2005    Mexico   PCR, MY09/M11, GP5/GP6, typed    21     50     42.0 
Jalouli 2010 India PCR, MY09/M11, not nested, agarose gel, typed 
with HPV16/18 specific primers, and sequenced 
15 62 24.2 
 Kaminagakura   2011   Brazil   PCR, GP5/GP6, agarose gel   22     114    19.3 
Kansky 2006 Slovenia   PCR, MY09/M11, GP5/GP6, WD72, WD76, 
..agarose gel, 
  typing by restriction fragment length   
..polymorphism 
4 44 9.1 
Klozar 2008 Czech PCR, GP5/GP6, not nested, chemoluminescence 
detection of hybridized amplicon, sequencing 
2 10 20.0 
  Klussmann  
2001 
 
Germany    PCR, consensus primers, HPV16 specific primers, 
..real time PCR 
 
4 
 
22 
 
18.2 
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 Koppikar 
 
2005 
 
India 
 
  PCR, L1 primers and GP5/GP6 
 
28 
 
83 
 
33.7 
 Koskinen 2003 Scandinavia PCR, MY09/MY11,GP5/GP6, SPF10, INNO-LiPA 
typing, 
FAP 59/64, CP65/70, CP66/69, type specific 
real time PCR 
7 13 53.8 
 
 Kristoffersen 
 
2012 
 
Scandinavia 
 
PCR, MY09/MY1, GP5/GP6 
 
8 
 
50 
 
16.0 
 Laco 2011 Czech 
Republic 
PCR, GP5/GP6 3 24 12.5 
 
 Lopes 
 
2011 
 
England 
 
PCR, GP5/6 Q-PCR HPV16/18 
 
2 
 
142 
 
1.4 
  Luo 2007 Tapei PCR, MY09/M11, GP5/GP6, typed by HPV gene 
chip 
13 51 25.5 
Montaldo 2010 Italy PCR, MY09/M11, agarose gel, sequenced 21 68 30.9 
Mork 2001 Scandinavia PCR, GP5/GP6 CpI, CpII E1, E6 specific primers 
for HPV6/11/16/18/33 
4 91 4.4 
  Neme   2006   Hungary   PCR, MY09/MY11, type specific, E2 for integration   33   79   41.8 
Pannone 2012 Italy PCR, MY09/M11, GP5/GP6, 8% polyacrylamide 
gel 
3 6 50.0 
Popovic 2010 Serbia PCR, consensus primers typing 6 60 10.0 
Ribeiro 2011 Multiple 
countries 
PCR, MY09/MY11, no nesting, HPV16E7 specific 
primers, agarose gel, typing by restriction fragment 
length polymorphism 
0 483 0.0 
Ringstrom 2002 USA PCR MY09/MY11, agarose gel, typing by restriction 
fragment length polymorphism 
2 41 4.9 
  Ritchie   2003   USA  PCR, MY09/MY11 agarose gel, dot blot, then  
.heminested PCR MY09. GP5 
10   94  10.6 
 Saghravanian   2011   Iran  PCR, GP5/GP6   3   21  14.3 
Sand 2000 Scandinavia PCR, MY09/MY11, agarose gel 3 24 12.5 
Schlecht 2011 USA PCR, MY09/11, dot blot 5 38 13.2 
Seraj 2011 Iran PCR, HPV 16/18 specific primers, agarose gel 25 94 26.6 
Sethi 2011 USA PCR, SPF10, INNO-LiPA typing 33 120 27.5 
Slebos 2006 USA PCR, MY09/MY11, sequenced 0 15 0.0 
Smeets 2007 Netherlands PCR, GP5/GP6 real time quantitative PCR 9 30 30.0 
Smith 2008 USA PCR,MY09/MY11, GP5/GP6, then typed 27 166 16.3 
Soderberg 2008 USA PCR, MY09/MY11, GP5/GP6, then sequenced 1 18 5.6 
Sugiyama 2007 Japan PCR, HPV16 E7 specific primers, agarose gel 24 66 36.4 
Tachezy 2005 Czech 
Republic 
PCR, GP5/GP6, then sequenced 3 12 25.0 
van Monsjou 2012 Netherlands PCR, INNO-LiPA typing 2 20 10.0 
Zhang 2004 China PCR, HPV 16/18 E6 specific primers, agarose gel 54 73 74.0 
Total    705 4,195  
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Expression of viral E6 and E7 oncoproteins is a well-known genetic alteration 
identified in the malignant behavior, because E6 degrades the p53 protein, and 
E7 inhibits the retinoblastoma tumor suppressor protein (pRb) of the host 
(Rampias et al., 2009). HPV16 E7 also inhibits p53 transcriptional activities and 
leads to the inactivation of the p53 dependent G1 cell cycle inhibitor (p21CIP1) 
(McLaughlin-Drubin et al., 2012). Another mechanism that is followed by HPV 
infected cell to drive proliferation is the fact that E7 inhibits the bind between 
retinoblastoma protein and E2F. As a result, E2F are released and can activate 
the S-phase genes (Doorbar, 2006). 
E6 and E7 oncogene repression has been reported by Rampias et al. to restore 
p53 and retinoblastoma tumor suppressor pathways and induce apoptosis in 
HPV16+ oropharyngeal cancer cell lines (Rampias et al., 2009). Therefore, 
patients with HPV+ tumors tend to have a better prognosis and substantially 
better survival rates after the radiation therapy or chemotherapy (Ang et al., 
2010; Posner et al., 2011; Rischin et al., 2010). Among patients with HPV+ 
tumors, the 5-year survival rates should be of approximately 75 to 80%, versus 
45 to 50% among patients with HPV- tumors (Ang et al., 2010). A study has 
confirmed that HPV+ SCCHN cancer cells are sensitive to radiation as 
compared to HPV-, which has an activating mutation in EGFR resulting in 
phosphorylation of Akt, which can be down-regulated by the HIV protease 
inhibitor Nelfinavir (NFV), resulting in sensitization to radiation (Gupta et al., 
2009). Moreover, HPV+ cancers have fewer mutations than tobacco-induced 
cancers, which make the treatment of HPV+ less aggressive (Psyrri & Cohen, 
2011). 
Multiple studies mentioned an inverse relationship between HPV and EGFR 
expression, since the low EGFR expression in HPV-related SCCHN might be 
associated with the favorable outcome of patients (Kumar et al., 2008). 
However, it remains unclear, whether HPV and EGFR mutations have a clinical 
impact in OSCC.  
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3. Aims 
The overall aim of this study was the investigation of the clinical impact of 
EGFR (E746-A750del) mutation and HPV on the survival of patients with 
OSCC.  
 
Specific aims were: 
1- To investigate the involvement of the EGFR (E746-A750del) mutation 
and HPV in OSCC. 
 
2- To determine, whether HPV infection is related to EGFR mutation or non-
smokers in OSCC. 
 
3- To evaluate, whether the mutation-specific EGFR (E746-A750del) 
expression and HPV is relevant for the survival of patients with OSCC. 
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4. Materials and Methods 
4.1. Patients and Tumor Specimen 
The records of 211 OSCC patients were reviewed retrospectively 
(Freudlsperger, Alexander, Reinert, & Hoffmann, 2010) after primary radical R0 
tumor resection in the Department of Oral and Maxillofacial Surgery, University 
Hospital Tuebingen over a period of ten years. We retrospectively reviewed the 
records of ten healthy individuals (normal oral mucosa tissues, n = 10), as well. 
The local ethics committee of the University Hospital Tuebingen approved this 
study (approval number: 001/2012BO2). An informed consent was obtained 
from each patient prior to surgical resection. The clinicopathological and follow-
up data were available for 191 out of 211 patients (n = 191/211). From 161 out 
of 191 patients, FFPE blocks for a representative immunohistochemical staining 
were available. Patients who presented insufficient follow-up data, 
nonresectable disease, and patients who were treated with preoperative 
antineoplastic therapies (chemoradiation / chemotherapy) were excluded from 
this study. The diagnosis of squamous cell carcinoma was confirmed by the 
Department of Pathology, University Hospital Tuebingen, from which the 
specimens were retrieved retrospectively. 
The used material was archival formalin-fixed and paraffin-embedded tissue 
(FFPE; formalin-fixed, paraffin-embedded) from routine histopathological work-
up. Experienced pathologists have selected the tumor blocks of paraffin-
embedded tissue using the routine Haematoxylin-Eosin (H.E.) stained sections. 
Regardless of the prior histopathology report, sections from all available tumors 
underwent intensive histopathological evaluation. Serial tissue sections were 
cut at 2 μm from formalin-fixed paraffin-embedded (FFPE) blocks using a 
microtome and fixed on microscope slides. Surgical margin status was 
determined on final histopathological assessment. Negative margins were 
considered to be greater than or equal to 10 mm from resection margin after 
tissue fixation, whereas close margins were deemed to be positive in all 
analysis.  
Materials and Methods 
 
22 
 
Tumor grading and staging was done according to WHO criteria, and the 7th 
edition of the TNM staging system by the UICC/ AJCC of 2010, respectively 
(Hamilton, 2000; Sobin LH & Ch., 2010). Tumor characteristics (UICC stage, 
pT-categories, pN-categories, cM-categories, infiltrated lymph nodes, residual 
tumor status, tumor size, site distribution) and patient characteristics (gender, 
age, personal history, habitual history) were collected in a database using 
(Excel, Microsoft). Tumor and patient characteristics are summarized in Table 
2. 
Follow-up data was obtained from the local tumor registry and the last follow-up 
was recorded from the last outpatient visit or the date of locoregional recurrence 
or tumor-specific death, respectively. 
 
Table 2: Clinicopathological characteristics and prognostic factors of 161 patients with 
OSCC measured by negative and positive EGFR E746-A750del specific mutation 
expression. 
Characteristics Number of Patients p-value 
 
Total 
n=161 
EGFR E746-A750del 
negative (<10%) 
n=121 (75%) 
EGFR E746-A750del 
positive (>10%) 
n=40 (25%) 
 
Age (y)    0.0916 
<60±11.8 80 (49.7%) 55 (69%) 25 (31%)  
≥60±11.8 81 (50.3%) 66 (81%) 15 (19%)  
Gender    0.5273 
Male 125 (77.6%) 92 (74%) 33 (26%)  
Female 36 (22.4%) 29 (80%) 7 (20%)  
Site distribution of OSCC    0.2026 
Lips 10 (6.2%) 10 (100%) 0 (0%)  
Tongue 36 (22.4%) 28 (78%) 8 (22%)  
Floor of the mouth 66 (41.0%) 48 (73%) 18 (27%)  
Palate 15 (9.3%) 10 (67%) 5 (33%)  
Buccal mucosa 9 (5.6%) 8 (89%) 1 (11%)  
Alveolar ridge 25 (15.5%) 17 (68%) 8 (32%)  
Histological Grading    0.9888* 
G1 39 (24.2%) 30 (77%) 9 (23%)  
G2 108 (67.1%) 80 (74%) 28 (26%)  
G3 13 (8.1%) 10 (77%) 3 (23%)  
G4 1 (0.6%) 1 (100%) 0 (0%)  
Tumor size    0.5263** 
pT1 64 (39.8%) 48 (75%) 16 (25%)  
pT2 40 (24.8%) 28 (70%) 12 (30%)  
pT3 17 (10.6%) 14 (82%) 3 (18%)  
pT4 40 (24.8%) 31 (78%) 9 (22%)  
Cervical lymph node 
metastasis 
   0.7363 
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pN0 118 (73.3%) 90 (76%) 28 (24%)  
pN1-3 43 (26.7%) 31 (72%) 12 (28%)  
UICC stage    0.8927*** 
UICC I 48 (29.8%) 39 (81%) 9 (19%)  
UICC II 36 (22.4%) 24 (67%) 12 (33%)  
UICC III 31 (19.3%) 25 (81%) 6 (19%)  
UICC IV 46 (28.6%) 33 (72%) 13 (28%)  
Smoking history    0.8598 
Never-smoker 44 (27.3%) 34 (77%) 10 (23%)  
Smoker 117 (72.7%) 87 (74%) 30 (26%)  
Alcohol consumption    0.2755 
Never 55 (34.2%) 38 (69%) 17 (31%)  
Ever 106 (65.8%) 83 (78%) 23 (22%)  
Locoregional recurrence    0.9047 
No 117 (72.7%) 87 (74%) 30 (26%)  
Yes 44 (27.3%) 33 (75%) 11 (25%)  
Abbreviations: y = years; G = grading; UICC = International Union against Cancer; *G1/2 vs. G3/4; **pT1/2 
vs. pT3/4; ***UICC I/II vs. UICC III/IV 
4.2. EGFR staining procedure and quantification 
of immunohistochemistry 
Immunohistochemistry was performed in 161 patients with OSCC. 
Unconjugated mutation-specific (Yu et al., 2009) EGFR (E746-A750del) (6B6) 
(Cell Signaling, Frankfurt am Main, Germany, rabbit anti-human mAb, dilution: 
1:250), and isotype control antibodies (BD Pharmingen, Heidelberg, Germany) 
were used for immunohistochemical analysis. The staining with unconjugated 
EGFR antibody (Dako, Glostrup, Denmark, mouse anti-human mAb, dilution: 
1:50) confirmed the presence of EGFR in tumor specimen. The tumor tissue 
FFPE blocks were used to cut 2 μm thick sections, which were mounted from 
warm water onto adhesive glass slides and dried for 24 h at 37°C. Then, the 
sections were put in xylene (2x10 minutes) to remove paraffin 
(deparaffinization), and then rehydrated through a graded ethanol series (3 
minutes 100% ethanol, 3 minutes 95% ethanol, 3 minutes 90% ethanol, 3 
minutes 80% ethanol, 3 minutes 70% ethanol) to distilled water. Subsequently, 
the sections were immersed into the pre-heated target retrieval solution using 
EDTA buffer pH 9.0 or citrate buffer pH 6.1 (Dako, Glostrup, Denmark) and 
boiled in a steamer. Endogenous peroxidase activity was blocked in a solution 
containing 3% H2O2, and endogenous biotin was blocked by Streptavidin/Biotin 
Blocking Kit (Vector Laboratories, Burlingame, CA, USA) according to the 
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manufactures instructions. After incubation of the sections overnight with 
primary antibody to EGFR (E746-A750del specific) (6B6) or control antibody in 
a humidified chamber, sections were washed with TBS, and incubated for 30 
min with the biotinylated secondary antibody (LSAB2 system multi-link swine 
anti-goat/mouse/rabbit immunoglobulin; Dako, Glostrup, Denmark) and 
horseradish peroxidase (HRP)-conjugated streptavidin (label). After washing 
and incubating for 5 minutes, the sections were visualized using 3,3′-
diaminobenzidine (DAB), which is oxidized by HRP in the presence of 0.3% 
H2O2. At the end, sections were counterstained in hematoxylin and covered 
with a glycergel (Dako, Glostrup, Denmark). 
For each case, five representative chosen high power fields (1 HPF = 0.237 
mm2) were studied and averaged to conﬁrm the histological diagnosis of EGFR 
expression in the tumor tissue, The extent of the staining, defined as the relative 
area of positive staining within the tumor cells relative to the whole tissue area, 
was semiquantitatively scored on a scale of 0 to 3 as follows: 0, <10%; 1, 10–
30%; 2, 30–60%; 3, >60%. The intensity of staining was scored using the 
following scale: no staining, 0; weak staining, 1+; moderate staining, 2+; and 
strong staining, 3+. The values of these two categories were multiplied and the 
combined score (0–9) for each specimen was approved. Cases were classified 
as: EGFR negative, 0 points; EGFR positive, 1–9 points. The immunostained 
sections were evaluated by two observers, who independently performed 
scoring while blinded to the diagnosis. 
In addition, ImageJ software (http:/rsbweb.nih.gov/ij/) coupled with 
immunomembrane plug-in (http://imtmicroscope.uta.fi/immunomembrane) was 
used for computer-assisted semi-quantitative analysis of EGFR expression, in 
order to assess the quantification of EGFR immunoreactivity in microscopically 
acquired JPEG images of OSCC samples. Staining completeness (0–10 points) 
and intensity (0–10 points) were added for a combined score (0–20 points) 
(Tuominen, Tolonen, & Isola, 2012). Cases were classified as the following: 
EGFR negative, 0 points; EGFR positive, 1–20 points. 5 images were collected 
per sample from EGFR positive slides to show representative tumor areas using 
10x and 20x objectives to assess precision (reproducibility/ repeatability) of 
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computer-assisted (semi-) quantitative analysis. Pictures were analyzed using a 
Canon camera (Krefeld, Germany). The photographed images were imported 
into the Microsoft Office Picture Manager. 
4.3. HPV genotyping 
In this study 211 patients with OSCC were screened based on SPF-10-PCR 
and Reverse Line Probe Assay LiPA Extra (SPF-10-PCR) for the presence of 
HPV genotypes. DNA isolation from FFPE samples was performed using a 
Qiasymphony device and the FFPE protocol (Qiagen, Hilden, Germany) and 
then analyzed with the INNO-LiPA Extra HPV prototype assay (Innogenetics, 
Inc, Gent, Belgium) according to the manufacturer’s instructions. Polymerase 
chain reaction (PCR) was performed in a separate room in the laboratory by 
following good laboratory practice. 
Each PCR reaction contained 10 μl input DNA in a total volume of 50 μl using 
reagents provided by Innogenetics. The reaction mixture was first heated at 
37°C for 10 minutes, and then at 94°C for 9 minutes, followed by 40 cycles each 
at 94°C for 30 seconds, annealing at 52°C for 45 seconds and extension at 
72°C for 45 seconds run on a MJ Thermocycler PCT 200. The PCR product 
was then denatured, and a 10-μl aliquot was hybridized at 49°C for 60 minutes 
onto one strip, followed by multiple washing steps. 
The reading of the hybridized strips was performed using a flatbed scanner with 
the use of LiRAS prototype software (Innogenetics, Inc), which displays the 
patterns and relative intensity of positive bands as arbitrary grey-tone values 
between 0.1 and 1.0. 
The INNO-LiPA Extra test allowed identification of  established high-risk-HPV 
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) (Gillison et al., 
2012; Schiffman, Clifford, & Buonaguro, 2009), and five known or putative high-
risk types (26, 53, 66, 73 and 82) (Cogliano et al., 2005; Munoz et al., 2003). 
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4.4. Statistical analysis 
Statistical analysis was performed using MedCalc Software (MedCalc Software 
bvba, Ostend, Belgium; http://www.medcalc.org; 2013). The disease-free 
survival (DFS) time was defined as the time from tumor resection until 
appearance of obvious locoregional recurrence or tumor conditional death, 
respectively. The Kaplan-Meier method was used to estimate the disease free 
survival times (Kaplan & Meier, 1958). For determination of the most significant 
variables contributing to survival status in univariate analysis, Hazard ratios 
(HR) were provided with 95% Confidence Interval (CI). The relation between 
two categorical variables was investigated by using Chi-Square test (χ2) and 
Fisher's exact test. The estimation of the accuracy (the degree of closeness of 
measurements of a quantity to that quantity's true value) between the two 
quantification methods of immunohistochemical analysis was performed by 
measuring non-parametric Kendall´s tau (т) correlation coefficient. All P values 
presented were 2-sided. P values less than 0.05 were considered statistically 
significant. 
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5. Results 
5.1. Comparison of observer semi-quantitative 
scoring with computer-assisted semi- 
quantitative analysis of EGFR (E746-A750del) 
expression 
A preliminary study was carried out to assess the accuracy between the two 
quantification methods of immunohistochemical analysis. There were significant 
correlations between the first (observer related semi-quantitative scoring) and 
the second (computer-assisted (semi)-quantitative analysis) assessment. EGFR 
(E746-A750del) expression: т = 0.983, p < 0.0001, 95% CI 0.974 to 0.990. 
5.2. Mutant EGFR (E746-A750del) expression is 
not associated with clinicopathological 
characteristics of OSCC 
EGFR (E746-A750del) expression was not detected in human normal oral 
squamous epithelium (n = 0/10 normal oral mucosa samples). On the contrary 
to stromal cells, EGFR (E746-A750del) expression was only located in the 
cytoplasm and the membrane of cancer cells (Figure 4). According to the 
analysis of EGFR (E746-A750del) expression, 25% of the patients (n = 40/161) 
had positive EGFR (E746-A750del) expression. Table 2 shows the 
clinicopathological characteristics and prognostic factors of 161 patients with 
OSCC. There was no association between positive EGFR (E746-A750del) 
expression (Figure 4) and any clinicopathological characteristics, prognostic 
factors, or social habits like smoking or alcohol consumption (Table 2). 
 
Results 
 
28 
 
Figure 4: Immunohistochemical single staining of mutant EGFR (E746–A750del) in OSCC. 
Representative images of IgG-control (a, no staining) and mutant positive EGFR expression (b 
and c) in OSCC (membranous and cytoplasmic staining pattern, brown). (b) The brown 
chromogen colour (3,3′- diaminobenzidine) indicates positive mutant EGFR staining, the blue 
colour shows the nuclear counterstaining by haematoxylin. (c) The pseudocoloured image 
shows the staining components of computer-assisted semi-quantitative analysis in mutant 
EGFR-positive OSCC cells. The computer-assisted red label indicates strong or complete 
staining, the green label indicates weak or incomplete staining. Original magnification: 200x.  
5.3. Prognostic value of mutant EGFR (E746-
A750del) in OSCC 
Patients were divided into two subgroups as follows: positive mutant (E746-
A750del) expressors and negative mutant EGFR (E746-A750del) expressors 
(dichotomous variables), in order to analyze the survival rates after successful 
curative surgical (R0) resection of OSCC. 
In this study population, cervical lymph node metastasis (pN1-3, HR = 2.1145, 
95% CI = 1.0272 to 4.3528, p = 0.0139) was shown to be an unfavorable 
predictor for the survival by univariate analysis of all (n = 161) OSCCs. The 
univariate analysis showed that tumor size (pT3/4, HR = 1.3865, 95% CI = 
0.6887 to 2.7914, p = 0.3080), grading (G3/4, HR = 0.9199, 95% CI = 0.2969 to 
2.8506, p = 0.8885), and advanced tumor stages (UICC III/IV, HR = 1.6734, 
95% CI = 0.9145 to 3.0623, p = 0.08) were not found to be unfavorable 
prognostic factors (Grimm et al., 2013). Social habits like alcohol consumption 
(alcohol consumption, HR = 2.1337, 95% CI = 1.1022 to 4.1304, p = 0.0593) or 
smoking (smoking history, HR = 1.6794, 95% CI = 0.8364 to 3.3721, p = 
0.2015) showed no significant impact on tumor specific survival. 
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Another two subgroups of patients were divided into positive and negative 
mutant EGFR (E746-A750del) expressors, to analyze the impact of EGFR 
(E746-A750del) in OSCC patients on the tumor related survival. The subgroup 
with positive EGFR (E746-A750del) mutation was not associated significantly 
with a better survival by contrast with the subgroup of patients without EGFR 
(E746-A750del) mutation (E746-A750del+: n = 40/161, p = 0.3397, HR = 
0.7008, 95% CI = 0.3574 to 1.3744, Figure 5a). 
As the cervical lymph node metastasis in this study population was found to be 
the only significant unfavorable factor in univariate analysis, multivariate 
analysis using the Cox Proportional Hazards Model was not performed. 
5.4. Prevalence and prognostic value of HPV 
status 
3 out of 211 OSCC samples were only HPV16+ (HPV16+: n = 3/211, 1.42%), 
using INNO-LiPA. The floor of the mouth was involved in each of the 3 cases as 
the affected anatomical site. All of the patients with HPV16 DNA positive had a 
positive history of smoking and alcohol consumption, but none of them were 
positively detected for EGFR (E746-A750del) mutation. The positive HPV status 
had no impact on tumor specific survival (HPV+: n = 3/191, p = 0.9188, HR = 
1.1078, 95% CI = 0.1385 to 8.8626, Figure 5b). 
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Figure 5: Survival curves for OSCC patients measured by mutant EGFR (E746–A750del) 
expression (n = 161/211) and HPV status (n = 191/211) 
Kaplan–Meier survival curves for disease-free survival (DFS) are stratified by positive mutant 
EGFR expression (EGFR+, dashed line, a), negative mutant EGFR expression (EGFR-, solid 
line, a), positive HPV status (HPV+, dashed line, b), and negative HPV status (HPV-, solid line, 
b). In the univariate Kaplan–Meier analysis, mutant EGFR expression (a) and HPV status (b) 
were not significantly associated with survival. The times at which the data were censored are 
indicated with short vertical lines. 
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6. Discussion 
The aim of this study was to analyze the role of EGFR (E746-A750del) mutation 
in the carcinogenesis of OSCC, since EGFR mutations have been reported to 
be involved in the development of many cancers such as lung cancers. 
Moreover, several studies have confirmed EGFR overexpression as the 
independent prognostic marker, which may probably decrease radiation 
sensitivity, increase the risk of recurrence and increase the tumor size (Ang et 
al., 2002; Chen et al., 2003; Gupta et al., 2002; Rubin Grandis et al., 1998; 
Shiraki et al., 2005). 
The incidence of OSCC has been decreased in the recent years because of the 
early detection and diagnosis of this cancer (Aquino et al., 2012). However, the 
correlation between EGFR mutations in OSCC with poor prognosis is still one of 
the biggest challenges in oral cancer research (Choi & Myers, 2008; Grobe et 
al., 2013; Monteiro et al., 2010; Oliveira & Ribeiro-Silva, 2011). The 
conventional grading, staging and site of tumor have been used for many years 
as major parameters of OSCC (Aquino et al., 2012). A better understanding of 
the molecular mechanisms and identification of potential oncogenes in oral 
cancer may provide more useful prognostic markers and probably a more 
effective treatment. 
One of the most useful diagnostic methods for detecting EGFR mutations is the 
use of mutation-specific antibodies when used in combination with DNA 
sequencing. Yu and Colleagues have generated specific antibodies for 
identifying EGFR mutations in exon 19 (E746-A750del) and in exon 21 (L858R 
point mutation). This method was performed on 340 paraffin-embedded NSCLC 
tissues, showing a sensitivity of 92% as compared with a sensitivity of 99% for 
DNA sequencing (Yu et al., 2009). In this study we were able to identify EGFR 
mutations by the EGFR mutation-specific antibodies. 
Our studies have found no association between EGFR (E746-A750del) 
mutation expression with any clinicopathological characteristics, prognostic 
factors, social habits (smoking, alcohol consumption), or tumor-specific survival. 
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Although EGFR has been reported in never-smoking patients with NSCLC 
(Marchetti et al., 2005; Shigematsu et al., 2005), our data shows no relation 
between EGFR mutations and never-smoking. 
Lee and colleagues have confirmed the prevalence of EGFR mutation in 7.3% 
of Asian patients with HNSCC by using RT-PCR (J. W. Lee et al., 2005). The 
single EGFR mutation has been detected in exon 19 (E746-A750del), which 
has been exclusively detected in our study. On the other hand, they have 
suggested that EGFR mutations may be rather functional alterations than non-
functional passenger changes (J. W. Lee et al., 2005; Pao, Miller, Venkatraman, 
& Kris, 2004). This differs from our study, since our survival analysis does not 
show any differences between positive and negative expressors, although 
EGFR (E746-A750del) expression has been detected in 25% of the patients of 
our study. 
Our results support the findings by Na et al showing a prevalence of EGFR 
(E746-A750del) mutation in OSCC (Na et al., 2007). Although these 
observations could not confirm its prevalence in the dysplastic lesions by the 
histopathological examination. These findings raise the question of whether 
EGFR (E746-A750del) mutation represents a predictor for TKI therapy in OSCC 
(J. W. Lee et al., 2005), because to date there is no evidence that EGFR (E746-
A750del) mutation is involved in the multi-step carcinogenesis of OSCC. 
EGFR mutations have been described to have a high response to small 
molecules tyrosine kinases. However, the clinical outcomes of EGFR mutations 
in NSCLC may be probably different from those in OSCC or tongue and tonsil 
carcinoma. Previous studies have indicated that TKI therapy has enhanced the 
survival in nearly 80% of patients with mutations, especially E746-A750del and 
the L858R point mutation in NSCLC (Kawahara et al., 2010; Lynch et al., 2004). 
Taking our data together with a previously published study from Na et al. on 
patients with tongue and tonsil carcinoma, EGFR mutations seem not to be 
associated with the survival outcome (Na et al., 2007). This result is in 
agreement with our study indicating that there is no significance between 
positive and negative expressors (p = 0.3397), in spite of the tendency of our 
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survival curve towards a better overall survival for patients with positive EGFR 
(E746-A750del) expression within the 5-year survival rate.  
Theoretically, all EGFR mutations may react to TKI in OSCC patients. Contrary 
to monoclonal antibodies, that block the extracellular ligand binding domain of 
EGFR, small-molecule EGFR inhibitors such as gefitinib and erlotinib inhibit its 
tyrosine kinase activity by binding directly to EGFR tyrosine kinase domain. 
Accordingly, cancers with EGFR tyrosine kinase domains mutations show 
relatively increased sensitivity to EGFR-TKI's (Gazdar, 2009). The results of a 
previous study, wherein none of OSCC samples were found to carry mutations 
in exon 19 and 21, have suggested that OSCC lesions may not response to 
EGFR-TKI's unlike NSCLCs (Mehta, Annamalai, & Ramanathan, 2014). 
Another study has found disparate survival outcomes according to the subtype 
of EGFR mutation, as the better survival outcomes were identified in Patients 
with NSCLC and EGFR exon 19 deletions in comparison with those with the 
L858R mutation (Jackman et al., 2006). It is unclear whether the survival 
outcomes could be enhanced in patients with EGFR mutations after the 
treatment of TKI in OSCC. Studies are ongoing to investigate the prognostic 
significance of EGFR mutations in OSCC and the effect of small-molecule 
targeted therapy on it. Increased knowledge in this field will probably spot the 
etiology of this mutation and its clinical impact. 
The prevalence of HPV DNA in oral carcinoma varies considerably between 
studies. Isayeva et al reviewed 60 publications on 4,195 patients with oral cavity 
SCC studied between the years 2000-2011, and determined the weighted 
prevalence of HPV DNA to be 20.2% (range: 0%-94.7%) (Isayeva et al., 2012). 
Our ﬁndings of HPV DNA in 1.42% of 211 OSCC patients show a low 
prevalence of HPV in OSCC, and are close to the results of recent several 
reports, which have determined the HPV prevalence to be from <2% (Francis, 
Dileep Kumar, Nalinakumari, Jayasree, & Kannan, 2013) to <6% (Lingen et al., 
2013). Although the results of Kantola et al could not detect any prevalence of 
HPV among 105 patients with tongue tumors (Kantola et al., 2000).  
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It was suggested that the occasional detection of HPV DNA in OSCC samples 
might be due to an incidental HPV colonization of the oral mucosa and not 
because of a viral infection (Kansky et al., 2003). While the high presence of 
HPV in some studies may refer to false-positive results, which overestimate the 
infection rates (Kansky et al., 2003; Miller & Johnstone, 2001; Rivero & Nunes, 
2006). The prevalence of HPV DNA in OSCC and the possibility of its 
involvement as a causative agent in the oral carcinogenesis are still 
controversial. Only few studies have examined the continuous prevalence of 
HPV in the Lymph Node Metastasis, tumoral recurrence or necropsies of OSCC 
samples (Hoffmann et al., 2005; Howell & Gallant, 1992). A study among 
patients with advanced OSCC has found that most of the HPV+ samples have 
been detected only in the matched samples of recidives and not in the primary 
tumor, which can demonstrate HPV to have a temporary prevalence in the 
progression of oral cancer (Oliveira, Ribeiro-Silva, Ramalho, Simoes, & 
Zucoloto, 2008). 
The disparately detected HPV prevalence between the studies may result from 
the different way in preserving, preparing and storing the HPV samples, distinct 
study populations, the different detection techniques and mixed anatomical 
areas. It is important to detect the location from which the samples were 
collected. Some previous studies have not mentioned the origin of the collected 
samples whether from the mobile tongue, which is a part of the oral cavity, or 
from the base of the tongue, which is a part of the oropharynx (Oliveira et al., 
2008). The distinction between oral cavity and oropharyngeal SCC is the 
subject of intense research interest and is believed to have a wide variety of 
effects on HPV prognosis, since HPV is more likely to be positive in 
oropharyngeal and Waldeyer's ring sites consisting of submucosal and 
subepithelial lymphatic tissues (Boy et al., 2006; Kreimer, Clifford, Boyle, & 
Franceschi, 2005). In both normal tissue or oropharyngeal SCC, the tonsillar 
crypt epithelium is capable of capturing and processing antigens, which let the 
virus enter the host basal cells. Furthermore, the crypt epithelium and lymphoid 
tissue may increase the chances of virus persistence in them. The oral rinse 
collected samples have shown to have much a higher rate of HPV than the 
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samples collected by oral swabs. This data raised the possibility of presenting 
the tonsillar tissue in the upper aerodigestive tract a reservoir of HPV. 
Moreover, It might be important for the immune response to HPV its persistence 
in tonsillar tissue (Syrjanen, 2004). Dahlgren et al have shown that HPV was 
positively detected in 2 (2.4%) of 85 of the tumor samples collected from the 
mobile tongue versus 10 (40%) of 25 of tumor samples collected from the base 
of tongue (Dahlgren et al., 2004). Similar to what has been observed by 
Dahlgren et al, another study has found an increased prevalence of HPV16 in 
oropharyngeal cancer patients compared with patients with oral cancer 
(Dahlstrom et al., 2003). HPV16 is believed to be found primarily in cancers 
originating from inflammation sites such as the tonsil, the cervix and the base of 
tongue (zur Hausen, 1996, 1999). 
Gillison et al have supposed that the survival of patients with HNSCC and HPV+ 
was better than the survival of those with HPV- (Gillison et al., 2000). The 
genotoxic chemotherapy may play a role in enhancing the survival in patients 
with HPV-positive cancer cell lines, as it induces apoptosis in these cells and 
reduces the expression of E6/E7 (Butz, Geisen, Ullmann, Spitkovsky, & Hoppe-
Seyler, 1996). Hence, cancers with HPV+ may be more sensitive to radiation 
and chemotherapy (DeWeese et al., 1997). As reported by other investigators, 
HPV-positive OSCC appears not to be significantly associated with better 
survival outcomes (Kaminagakura et al., 2012; Sugiyama et al., 2007). On the 
contrary, previous published data suggested that HPV is correlated with poor 
survival and an increased risk of recurrence in OSCC patients who receive 
radical surgery (L. A. Lee et al., 2012). Therefore, there is still a lack of 
information on clinical impact of HPV in the context of OSCC due to small 
samples of enrolled patients, relatively low rates of detected HPV (less than 
10%), inclusion patients with cancers in both the oral cavity and oropharynx, 
different treatment modalities and different cultural behaviors and regions 
(Dahlgren et al., 2004; Herrero et al., 2003; Joo et al., 2012; S. Y. Lee et al., 
2010; Liang, Lewis, Foote, Smith, & Kademani, 2008; Machado et al., 2010; Na 
et al., 2007; Pathare et al., 2011; Shima et al., 2000). 
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HPV16 is the most frequent subtype detected in oral cancers (Isayeva et al., 
2012), as found in this study, since the single observed genotype was HPV16. 
According to the smoking and alcohol drinking history, all HPV16+ patients in 
our study were smokers and alcoholics. In accordance with our findings, a 
recent study reported that among heavy smokers or heavy drinkers, the risk of 
OSCC is greater in HPV+ patients compared with HPV- patients (Smith, 
Rubenstein, Haugen, Pawlita, & Turek, 2012). Accordingly, the most of the 
patients with HPV-positive OSCC are smokers and/or alcoholics (L. A. Lee et 
al., 2012). Based on the study of Lee et al, long-lasting betel quid chewing may 
result in damaging the HPV-infected oral epithelium and can accumulate 
chemicals, which can play a role in the HPV carcinogenesis (L. A. Lee et al., 
2012). 
In our study, EGFR (E746-A750del) mutation was negative in all HPV16+ 
patients. Due to the small number of HPV-positive samples in our study, which 
may lead to random results, it was not possible to draw any conclusion from this 
context and the detected affected anatomical site (floor of the mouth). 
There are some limitations to this work. It was a retrospective study, not a 
prospective cohort research. Accordingly, the collecting of precise information 
during the patient follow-up period was not always possible. In addition, FFPE 
tissue blocks for HPV PCR were collected from 211 patients, whereas the 
follow-up data were available from only 191 patients. Of these 191 patients, 
FFPE blocks for a representative immunohistochemical staining were available 
for 161 patients. Validation of these findings requires future prospective studies 
providing fresh tumor samples and a multi-method approach for analyzing the 
HPV status. 
The detection sensitivity of HPV may be decreased for the FFPE samples that 
contained degraded DNA and RNA (Lingen et al., 2013). Therefore, our 
observed rate of 1.42% may have been underestimated. Perhaps the most 
used HPV DNA detection is usually PCR, and the detection of HPV-associated 
carcinogenesis depends on p16 overexpression, demonstration of HPV E6/E7 
RNA, and wild type p53, which have not been analyzed in this survey (Isayeva 
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et al., 2012). A lot of researches do not focus attention on P16 expression as an 
surrogate biomarker for HPV-associated OSCC, because these studies do not 
identify the sensitivity and specificity of p16 overexpression. Therefore, future 
studies must be conducted in order to fully understand the P16 expression in 
OSCC (Isayeva et al., 2012). 
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7. Summary 
Oral squamous cell carcinoma (OSCC) takes the sixth place among the most 
common cancers worldwide. In spite of the vast amount of research and the 
advances in diagnosis and treatment modalities, the survival rates of patients 
with oral cancer have not significantly improved in the last decades. Prognostic 
and predictive biomarkers of treatment outcome have been identified as 
causative factors for other tumor entities but they are still lacking for OSCC. The 
primary purpose of this study is the analysis of two important biomarkers - 
Epidermal Growth Factor Receptor (EGFR) and human papillomavirus (HPV), 
which may have a promising impact on the diagnosis and therapy of OSCC. 
It has become apparent that an abnormal activation of EGFR gene is correlated 
with self-sufficiency in growth signals, evading apoptosis and other hallmarks of 
cancer. Moreover, EGFR (E746-A750del) mutations can increase the sensitivity 
to EGFR tyrosine kinase inhibitors such as gefitinib and erlotinib in patients with 
advanced non-small-cell lung cancer. Therefore, testing for mutations 
in EGFR is an important step in the treatment-decision-pathway. However, the 
prognostic impact of EGFR (E746-A750del) mutation and HPV on OSCC 
remains unclear. 
This study was designed to analyze the clinical impact of EGFR (E746-A750del) 
mutation and human papillomavirus (HPV) in OSCC. 211 patients with OSCC 
treated by primary radical tumor resection were retrospectively enrolled in this 
study. Using INNO-LiPA Extra, high-risk-HPV types were analyzed in all 211 
OSCC samples. The EGFR (E746-A750del) expression was analyzed in 161 
OSCC samples by immunohistochemistry. The expression results were 
associated with clinicopathological characteristics and survival outcome. The 
disease-free survival times were estimated using the Kaplan-Meier method. 
Multivariate analysis using the Cox Proportional Hazards Model was not 
performed for these parameters. 
Our findings showed low prevalence of EGFR (E746-A750del) expression and 
HPV in all cancer specimens. Positive EGFR (E746-A750del) expression was 
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detected in 25% of the patients (n = 40/161), while 1.42% of them were HPV16 
positive (HPV16+: n = 3/211). EGFR (E746-A750del) mutation was not 
significantly associated with survival of the patients. Lymph node metastasis 
was shown to be the only significant unfavorable factor in multivariate analysis. 
Social habits like alcohol consumption or smoking had no significant effect on 
the tumor specific survival. Positive HPV status had no impact on tumor specific 
survival in OSCC. 
On the basis of the results of this research it can be concluded that in OSCC 
EGFR (E746-A750del) expression is not associated with clinicopathological 
characteristics, prognostic factors, or social habits; HPV does not seem to be 
correlated with the survival of patients. Our results may contribute to a better 
understanding of the prognostic impact of EGFR mutations and HPV in OSCC 
leading to guidance on better diagnosis and therapeutic decisions in the future. 
Further studies are needed to investigate the prognostic impact of EGFR 
mutations in OSCC particularly in relation to small molecules. 
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9. Zusammenfassung 
Mundhöhlenkarzinome gehören zu der sechsthäufigsten Tumorentität weltweit. 
Trotz Fortschritten in Diagnose und therapeutischen Maßnahmen konnte die 
Überlebensrate von Patienten mit Mundhöhlenkarzinom in den letzten 
Jahrzehnten nicht signifikant gesteigert werden. 
Während für andere Tumorentitäten bereits standardisierte prognostische 
Biomarker identifiziert wurden, fehlen diese bis heute für das 
Mundhöhlenkarzinom. 
Das Ziel dieser Studie war anhand der „Hallmarks of Cancer“ (Krebsmerkmale) 
gewebebasierte Biomarker zu analysieren, wodurch möglicherweise langfristig 
eine schonendere und bessere Therapie für Patienten mit Mundhöhlenkarzinom 
angeboten werden kann. 
Der Nachweis eines abnormal aktivierten sowie mutierten epidermalen 
Wachstumsfaktor Rezeptors (EGFR) in Tumorzellen kann als Hinweis auf 
Apoptoseresistenz und Selbstversorgung mit Wachstumssignalen (Hallmarks of 
Cancer) verstanden werden. In bisherigen Arbeiten konnte gezeigt werden, 
dass Mutationen im EGFR-Gen (E746-A750del) die Sensitivität von Patienten 
mit fortgeschrittenem nicht-kleinzelligem Lungenkarzinom gegenüber EGFR-
basierten Tyrosinkinaseninhibitoren wie Gefitinib und Erlotinib erhöhen. Aus 
diesem Grund ist die Untersuchung von EGFR-Mutationen ein wichtiger Schritt 
auf dem Weg zu neuen Behandlungsmethoden.   
In der Literatur wird das humane Papillomaviren (HPV) mit Karzinogenese von 
Kopf-Hals Tumoren (Plattenepithelkarzinomen des Kopf-/Halsbereiches) 
assoziiert und mit Apoptoseresistenz von Tumorzellen in Verbindung gebracht, 
insbesondere mit orpharyngealen Plattenephithelkarzinomen. 
Die Analyse der Prävalenz der EGFR-Mutation (E746-A750del) beim 
Mundhöhlenkarzinom ist bislang unbekannt. Diese Studie befasste sich daher 
insbesondere mit der Analyse der EGFR-Mutation (E746-A750del) sowie des 
HPV Status auf die Prognose des Mundhöhlenkarzinoms.  
Zusammenfassung 
 
52 
 
In dieser Studie wurde retrospektiv 211 Tumorgewebeproben mit histologisch 
gesichertem oralen Plattenepithelkarzinom mittels INNO-LiPa Extra auf 
Hochrisikotypen von HPV hin untersucht. Die Expression der EGFR-Mutante 
E746-A750del wurde in 161 Tumorgewebeproben immunhistochemisch 
analysiert. Die Ergebnisse dieser Expressionsanalysen wurden anschließend 
mit klinisch-pathologischen Verlaufsparametern und Überlebensraten assoziiert. 
Die Überlebensrate der Tumorpatienten wurde in Bezug auf die EGFR (E746-
A750del) und HPV Expression univariat mit der Kaplan-Meier-Methode 
ermittelt.  
Die Untersuchungen zeigten eine geringe Expression von EGFR (E746-
A750del) und HPV in den analysierten Proben. In 25% der Patientenproben 
(n=40/161) konnte eine Expression der EGFR-Mutante nachgewiesen werden, 
während nur 1.42% der Proben positive Resultate für HPV16 aufwiesen 
(n=3/211). In Assoziation mit den klinisch-pathologischen Verlaufsparametern 
zeigte sich, dass die Subpopulation der EGFR (E746-A750del)-positiv 
getesteten Patienten keine signifikant bessere oder schlechtere 
Überlebensrate, verglichen mit den EGFR (E746-A750del)-negativen Patienten 
aufwies. In der multivariaten Analyse war Lymphknotenmetastasierung der 
einzig prognostisch unabhängig Faktor für signifikant schlechtes 
tumorbedingtes Überleben. Personenbezogene Risikofaktoren wie 
Alkoholkonsum oder Rauchen hatten keinen signifikanten Einfluss auf die 
tumorspezifische Überlebensrate. Des Weiteren konnte auch kein Einfluss des 
HPV-Status auf die tumorspezifische Überlebensrate für das 
Mundhöhlenkarzinom gezeigt werden. 
Auf Basis der erzielten Ergebnisse aus dieser Studie kann schlussgefolgert 
werden, dass die Expression der EGFR-Mutante (E746-A750del) keinen 
Einfluss auf klinisch-pathologische Verlaufsparameter, prognostische Faktoren 
oder persönliche Risikofaktoren wie Nikotin- und Alkoholabusus hat. Auch das 
Vorhandensein einer HPV-Infektion scheint nicht mit dem Überleben der 
entsprechenden Patienten assoziiert zu sein.  
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Die in dieser Arbeit erzielten Ergebnisse können jedoch zu einem besseren 
Verständnis der prognostischen Relevanz von EGFR-Mutationen und HPV 
beim Mundhöhlenkarzinom beitragen. Diese basiswissenschaftlichen 
Ergebnisse tragen dazu bei, in Zukunft notwendige Therapieentscheidungen 
besser zu untermauern. Weiterführende Arbeiten zur prognostischen Relevanz 
von EGFR-Mutationen sind jedoch unerlässlich, besonders im Zusammenhang 
mit klinischen Studien und Therapieansätzen durch spezifische 
Tyrosinkinaseinhibitoren (sog. `small molecules´). 
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